These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23139119)

  • 21. Platelet-vessel wall interactions in thrombosis and restenosis role of von Willebrand factor.
    Hoylaerts MF
    Verh K Acad Geneeskd Belg; 1997; 59(3):161-83. PubMed ID: 9490916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High shear stress attenuates agonist-induced, glycoprotein IIb/IIIa-mediated platelet aggregation when von Willebrand factor binding to glycoprotein Ib/IX is blocked.
    Iijima K; Murata M; Nakamura K; Kitaguchi T; Handa M; Watanabe K; Fujimura Y; Yoshioka A; Ikeda Y
    Biochem Biophys Res Commun; 1997 Apr; 233(3):796-800. PubMed ID: 9168936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers.
    Oney S; Nimjee SM; Layzer J; Que-Gewirth N; Ginsburg D; Becker RC; Arepally G; Sullenger BA
    Oligonucleotides; 2007; 17(3):265-74. PubMed ID: 17854267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific inhibiting effects of Ilexonin A on von Willebrand factor-dependent platelet aggregation under high shear rate.
    Li M; Wu WK; Liu L; Liao FL; Shinohara Y; Handa S; Goto S
    Chin Med J (Engl); 2004 Feb; 117(2):241-6. PubMed ID: 14975210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes.
    Spiel AO; Gilbert JC; Jilma B
    Circulation; 2008 Mar; 117(11):1449-59. PubMed ID: 18347221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion, decreases platelet aggregation and intimal hyperplasia in a rat carotid endarterectomy model.
    Cruz CP; Eidt J; Drouilhet J; Brown AT; Wang Y; Barnes CS; Moursi MM
    J Vasc Surg; 2001 Oct; 34(4):724-9. PubMed ID: 11668330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial.
    Markus HS; McCollum C; Imray C; Goulder MA; Gilbert J; King A
    Stroke; 2011 Aug; 42(8):2149-53. PubMed ID: 21700934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current state and novel approaches of antiplatelet therapy.
    Metharom P; Berndt MC; Baker RI; Andrews RK
    Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1327-38. PubMed ID: 25838432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of von Willebrand factor-GPIb/IX/V interactions as a strategy to prevent arterial thrombosis.
    Bonnefoy A; Vermylen J; Hoylaerts MF
    Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):257-69. PubMed ID: 15030285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
    de Romeuf C; Hilbert L; Mazurier C
    Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time.
    Wadanoli M; Sako D; Shaw GD; Schaub RG; Wang Q; Tchernychev B; Xu J; Porter TJ; Huang Q
    Thromb Haemost; 2007 Aug; 98(2):397-405. PubMed ID: 17721623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low shear stress can initiate von Willebrand factor-dependent platelet aggregation in patients with type IIB and platelet-type von Willebrand disease.
    Murata M; Fukuyama M; Satoh K; Fujimura Y; Yoshioka A; Takahashi H; Handa M; Kawai Y; Watanabe K; Ikeda Y
    J Clin Invest; 1993 Sep; 92(3):1555-8. PubMed ID: 8376606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Development of a novel aptamer blocking the interaction between the VWF A1 domain and platelet GP Ib for the treatment of arterial thrombosis].
    Matsumoto M; Harada K
    Rinsho Ketsueki; 2022; 63(5):393-402. PubMed ID: 35662162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab.
    Sakai K; Someya T; Harada K; Yagi H; Matsui T; Matsumoto M
    Haematologica; 2020 Nov; 105(11):2631-2638. PubMed ID: 33131252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel interpretation of the role of von Willebrand factor in thrombotic microangiopathies based on platelet adhesion studies at high shear rate flow.
    Galbusera M; Remuzzi A; Benigni A; Rossi C; Remuzzi G
    Am J Kidney Dis; 2000 Oct; 36(4):695-702. PubMed ID: 11007670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-glycoprotein Ib causes platelet aggregation: different effects of blocking glycoprotein Ib and glycoprotein IIb/IIIa in the high shear filterometer.
    O'Brien JR; Etherington MD
    Blood Coagul Fibrinolysis; 1998 Sep; 9(6):453-61. PubMed ID: 9818994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VWF attributes--impact on thrombus formation.
    Reininger AJ
    Thromb Res; 2008; 122 Suppl 4():S9-13. PubMed ID: 18929523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased platelet deposition on extracellular matrix under flow conditions in patients with antiphospholipid syndrome who experience thrombotic events.
    Levy Y; Shenkman B; Tamarin I; Pauzner R; Shoenfeld Y; Langevitz P; Savion N; Varon D
    Arthritis Rheum; 2005 Dec; 52(12):4011-7. PubMed ID: 16320349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.